glp 1 agonist and dpp 4 inhibitor Glucagon-like peptide-1 GLP-1-RA and DPP-4 inhibitors in

Why wouldnt Eliquis or Pradaxa (which do not appear to be the lowest cost option in Canada) forgo participating in the Ontario market

Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes a meta-analysis

Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

This platform could prove transformative, enabling the construction of multi-agonists more rapidly and efficiently and allowing promising biological discoveries to be translated into practical therapies with far greater speed

obesity GLP-1 market size is calculated at USD 3.69 billion in 2025 and is expected to reach nearly USD 30.41 billion in 2035, accelerating at a strong CAGR of 23.48% between 2026 and 2035

Clinical trials show up to about 11% average weight loss after 72 weeks and improved A1C in adults with obesity or type 2 diabetes who took the drug